What is the latest price of a box of resmetirom?

Resmetirom - Rezdiffra is a new oral drug mainly used to treat non-alcoholic steatohepatitis (NASH) and adult patients with moderate to severe liver fibrosis. It regulates liver lipid metabolism, reduces liver fat content, improves liver fibrosis, and reduces inflammation and oxidative stress by selectively activating thyroid beta receptors (THR-β). This mechanism gives resmetirom unique advantages in the treatment of non-cirrhotic NASH, especially for patients who hope to improve liver health through drug intervention.

In overseas markets, the original drug of Resimeterol is usually sold in 60mg, 80mg and 100mg specifications, with 30 tablets per box. The latest selling price of the US version of the original drug is about 60,000 yuan, which reflects its high research and development costs and the characteristics of being a new innovative drug. At the same time, generic drugs and some Southeast Asian versions are also circulating in the market, such as the Laos ASEAN version and the Laos Lucius version. The active ingredients are basically the same as the original drugs, but the selling price has dropped significantly. It is currently about 1,500 to 2,000 yuan (the price will fluctuate due to the exchange rate).

It should be noted that resmetirol is not yet available in China and is not included in medical insurance, which means that it is temporarily difficult for domestic patients to obtain it through conventional channels. Although the overseas version is more expensive, it still provides access to the drug for some patients in clinical research or international medical tourism. After the domestic launch, price, medical insurance policy and accessibility still need to wait for the final decision of the National Food and Drug Administration and medical insurance policy.

In practical applications, resmetirol usually needs to be combined with lifestyle intervention, including reasonable diet and moderate exercise, to obtain optimal efficacy. Studies have shown that this combined intervention not only improves liver fat content but also significantly reduces the risk of liver fibrosis progression.

Reference materials:https://www.drugs.com/monograph/resmetirom.html